A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Biomedicines. 2022 Aug 28;10(9):2105. doi: 10.3390/biomedicines10092105.

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon but life-threatening diseases mostly caused by drugs. Although various systemic immunomodulating agents have been used, their therapeutic efficacy has been inconsistent. This study aimed to provide an evidence-based review of systemic immunomodulating treatments for SJS/TEN. We reviewed 13 systematic review and meta-analysis articles published in the last 10 years. The use of systemic corticosteroids and IVIg is still controversial. An increasing number of studies have suggested the effectiveness of cyclosporine and biologic anti-TNF-α in recent years. There were also some promising results of combination treatments. Further large-scale randomized controlled trials are required to provide more definitive evidence of the effectiveness of these treatments. The pathogenesis of SJS/TEN has been elucidated in recent years and advances in the understanding of SJS/TEN may inspire the discovery of potential therapeutic targets.

Keywords: Stevens–Johnson syndrome; meta-analysis; toxic epidermal necrolysis.

Publication types

  • Review

Grants and funding

This research received no external funding.